Laila Goodridge on Questions Passed as Orders for Returns

With regard to Health Canada’s approval of licenses to organizations to possess, produce, sell or distribute substances, as per British Columbia’s subsection 56(1) exemption under the Controlled Drugs and Substances Act or any other similar type of government granted exemptions: (a) how many organizations are currently being reviewed for a Controlled Drug and Substances Dealer’s License (“Dealer’s License”), broken down by (i) cocaine, (ii) hydromorphone, (iii) diacetylmorphine, (iv) fentanyl, (v) methamphetamine, (vi) psilocybin, (vii) psilocin, (viii) 3,4-methylenedioxymethamphetamine, (ix) amphetamine, (x) oxycodone, (xi) MDMA, (xii) morphine, (xiii) opium, (xiv) other substances, broken down by substance; (b) how many organizations have been approved for a Controlled Drug and Substances Dealer’s License (“Dealer’s License”), broken down by (i) cocaine, (ii) hydromorphone, (iii) diacetylmorphine, (iv) fentanyl, (v) methamphetamine, (vi) psilocybin, (vii) psilocin, (viii) 3,4-methylenedioxymethamphetamine, (ix) amphetamine, (x) oxycodone, (xi) MDMA, (xii) morphine, (xiii) opium, (xiv) other substances, broken down by substance; (c) how many inspections of license holders have been conducted by Health Canada since British Columbia’s exemption was granted; (d) what number of enforcement actions have been taken by Health Canada against license holders found to be in non-compliance, including the number of licenses refused, suspended or revoked and the number of administrative monetary penalties issued; (e) what criteria were used to approve Adastra Labs for (i) their Controlled Drug and Substances Dealer's License, (ii) the amendment to include cocaine, on February 17, 2023; (f) is the claim in the February 22, 2023, press release from Adastra Labs that the company “received approval from Health Canada on February 17, 2023, for its amendment to include cocaine as a substance that the Company can legally possess, produce, sell and distribute” accurate and, if not, what is inaccurate about the claim; and (g) what are the details of all such licenses approved by Health Canada since January 1, 2022, including, for each, the (i) vendor, (ii) date of the approval, (iii) specific substances approved, (iv) type of activities permitted with the license (possession, production, distribution, sale)?